QLS1128 / Qilu Pharma - LARVOL DELTA

On the origins of SARS-CoV-2 main protease inhibitors. (PubMed, RSC Med Chem) - "In less than 3 years of research, 4 inhibitors of SARS-CoV-2-M have actually been authorized for COVID-19 treatment (nirmatrelvir, ensitrelvir, leritrelvir and simnotrelvir) and more such as EDP-235, FB-2001 and STI-1558/Olgotrelvir or five undisclosed compounds (CDI-988, ASC11, ALG-097558, QLS1128 and H-10517) are undergoing clinical trials. Since many series of covalent SARS-CoV-2-M inhibitors owe some of their origins to previous work on other proteases, we first provided a description of various inhibitors of cysteine-bearing human caspase-1 or cathepsin K, as well as inhibitors of serine proteases such as human dipeptidyl peptidase-4 or the hepatitis C protein complex NS3/4A. This is then followed by a description of the results of the approaches adopted (repurposing, structure-based and high throughput screening) to discover coronavirus main protease inhibitors."

Journal • Review • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • CASP1 • CTSK • SPECC1

A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19 (clinicaltrials.gov) - P3 | N=1220 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P3 trial • Infectious Disease • Novel Coronavirus Disease

A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19 (clinicaltrials.gov) - P2 | N=360 | Recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P2 trial • Infectious Disease • Novel Coronavirus Disease

A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants (clinicaltrials.gov) - P1 | N=86 | Recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

Combination therapy • New P1 trial • Infectious Disease • Novel Coronavirus Disease